• John H. Carstens

    Type Size
    Since 1994 an ASBMR Annual Meeting scientific session on the treatment of osteoporosis is presented in honor of John H. Carstens, Jr., M.D. Dr. Carstens was a well-respected leader of clinical research in the pharmaceutical industry. He served as Director of Medical Research in the Neuroendocrinology Department at Sandoz (now Novartis Pharmaceuticals Corporation) for ten years. Dr. Carstens was responsible for the development of the nasal spray salmon calcitonin for the treatment of Paget's disease and osteoporosis, as well as other drugs developed for use in arthritis, organ transplantation, and hormonal disorders. In addition to his role in drug development, Dr. Carstens was also noted for providing research funding to many investigators to pursue questions of medical and scientific interest. He served as mentor to many associates who have gone on to successful careers in the pharmaceutical and academic communities.

    In addition, he was an outstanding orthopedic surgeon who specialized in hand surgery, but who also mastered the complexities of bone and joint disease. With an endowment from Sandoz (now Novartis Pharmaceuticals Corporation), the ASBMR honors Dr. Carstens’ remarkable scientific achievements in the field of bone and mineral metabolism and dedication to education and research.